|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 April 2006, Vol. 107, No. 8, pp. 3091-3097. Prepublished online as a Blood First Edition Paper on December 29, 2005; DOI 10.1182/blood-2005-10-4057.
GENE THERAPY Correction of canine X-linked severe combined immunodeficiency by in vivo retroviral gene therapyFrom the Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD; Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia; and Veterinary Pathology, Microbiology and Immunology, School of Veterinary Medicine, University of California, Davis.
X-linked severe combined immunodeficiency (XSCID) is characterized by profound immunodeficiency and early mortality, the only potential cure being hematopoietic stem cell (HSC) transplantation or gene therapy. Current clinical gene therapy protocols targeting HSCs are based upon ex vivo gene transfer, potentially limited by the adequacy of HSC harvest, transduction efficiencies of repopulating HSCs, and the potential loss of their engraftment potential during ex vivo culture. We demonstrate an important proof of principle by showing achievement of durable immune reconstitution in XSCID dogs following intravenous injection of concentrated RD114-pseudotyped retrovirus vector encoding the corrective gene, the interleukin-2 receptor  chain (c). In 3 of 4 dogs treated, normalization of numbers and function of T cells were observed. Two long-term–surviving animals (16 and 18 months) showed significant marking of B lymphocytes and myeloid cells, normalization of IgG levels, and protective humoral immune response to immunization. There were no adverse effects from in vivo gene therapy, and in one dog that reached sexual maturity, sparing of gonadal tissue from gene transfer was demonstrated. This is the first demonstration that in vivo gene therapy targeting HSCs can restore both cellular and humoral immunity in a large-animal model of a fatal immunodeficiency.
Gene therapy offers promise of clinical benefit and perhaps cure for many genetic diseases. The first successful gene therapy trial was in treatment of X-linked severe combined immunodeficiency (XSCID), a life-threatening primary immunodeficiency caused by mutations in the common gamma chain ( c) subunit of various interleukin (IL) receptors, thus presenting with absence of normal lymphocyte function and profound immunologic abnormalities.1,2 In this clinical study, XSCID infants received autologous hematopoietic stem cells (HSCs) transduced ex vivo with an oncoretroviral vector carrying the c gene, resulting in immune reconstitution and reversal of the clinical phenotype in 10 of 11 treated boys.3,4 This trial documented that gene therapy alone can successfully provide long-term clinical benefit for a human disease. The immune reconstitution was similar to that observed in XSCID boys who successfully received bone marrow transplants, namely complete reconstitution of the T-cell population with c+ (normal) T cells, with only approximately 1% of the B lymphocytes being derived from transduced cells. Unfortunately, 3 of the gene therapy–treated boys developed T-cell leukemias attributed to insertional mutagenesis approximately 3 years following treatment, indicating that gene therapy is not without potential serious side effects.4-6 To date, all human clinical gene therapy protocols targeting HSCs are based upon ex vivo gene transfer requiring that HSCs be mobilized, isolated, and cultured ex vivo for 4 to 5 days in the presence of multiple cytokines,3,7-10 which can cause differentiation and loss of homing abilities of the cells. Numerous animal studies have reported HSCs cultured ex vivo under similar conditions and cytokine exposure to be at a disadvantage compared with freshly isolated cells in terms of both their short-term and long-term engraftment potential that was evident as early as 3 to 6 days of culture.11-14 These studies raise the question of whether exhaustion of stem cells might result from growth factor stimulation ex vivo.15 Limitation of number of HSCs that can be isolated and potential further loss of cells during processing may ultimately lead to a low dose of transduced cells for transplantation.
An attractive alternative would be to transduce HSCs in vivo within their natural environment, thereby eliminating the necessity for ex vivo manipulation of the target cell. Low-level gene marking of blood lineages has previously been observed after intravenous administration of retrovirus vector to newborn dogs to treat mucopolysaccharidosis VII,16 suggesting the possibility that an in vivo approach to gene therapy could cure XSCID because of the potent selective growth advantage conferred on T lymphocytes by
XSCID dogs
All experiments were performed in accordance with protocols approved by the University of Pennsylvania Institutional Animal Care and Use Committee (IACUC no. 360600). The colony of XSCID dogs used in this study carry a 4–base pair deletion in the first exon of Retroviral vector production
RD114-pseudotyped MFGS–canine- Analysis of transgene expression by flow cytometry and confocal microscopy
Peripheral dog blood was lysed (ACK lysis buffer), washed with phosphate-buffered saline (PBS), and then analyzed for GFP and/or after staining with phycoerythrin (PE)– or biotin-labeled monoclonal antibodies specific against canine CD3 (CA17.2A12), CD21 (CA2.1D6), CD45RA (CA4.1D3), CD14 (TUG4), or neutrophils23 (Serotec, Raleigh, NC). Analysis was performed using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA) or confocal microscopy. Confocal images were collected on a Leica TCS-NT/SP confocal microscope (Leica Microsystems, Exton, PA) using a 63 x/1.32 numeric aperture oil immersion objective, zoom 4 x. Fluorochromes were excited using an argon laser at 488 nm for GFP, 568 nm for Alexa-Fluor 568 (Molecular Probes, Eugene, OR). Images were processed using Leica TCS-NT/SP software version 2.61 and Adobe Photoshop 7.0 (Adobe Systems, San Jose, CA). The In vitro functional assessment of PBMCs by evaluation of signaling and proliferative responses to cytokine stimulation
Stimulation of
TCR V
We have recently cloned and sequenced 43 different canine T-cell receptor Assessment of humoral immune function Serum IgG was determined by radial immunodiffusion using canine IgG–specific plates (Bethyl Lab, Montgomery, TX). At normalization of serum IgG levels, the 2 long-term–surviving dogs (1547 and 1655) were immunized with a modified live canine parvovirus (CPV) and canine distemper virus (CDV) vaccine and serum levels of specific IgG were determined by either a passive hemagglutination (for CPV) or serum neutralization (for CDV) assay. Multiplex quantitative PCR analysis of vector copy number Genomic DNA for quantitative PCR (qPCR) was extracted from lysed whole blood or magnetic bead–isolated CD3+ T cells (Serotec) separated in GFP+ and GFP– cells by fluorescence-activated cell sorting. Sperm DNA was extracted as previously reported.26 Vector copy number was determined by real-time TaqMan PCR (Applied Biosystems, Foster City, CA). By using a multiplex method, sequences of both the retroviral vector (MFGS) and the housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) were amplified in the same well to allow normalization of DNA input most accurately. A primer/probe set located within the packaging signal of the MFGS vector was used: forward primer, 5'-CGCAACCCTGGGAGACGTCC-3'; probe, 5'-6-FAM-CCGTTTTTGTGGCCCGACCTGATAMRA; reverse primer, 5'-CGTCTCCTACCAGAACCACATATCC-3'. The primers and probe for detection of the HPRT gene were as follows: forward primer, 5'-GGATTTGAAATTCCAGACAAGTTTGTTG-3'; probe, 5'-VIC-GCCCTTGACTATAATGAATACTTCAGG-TAMRA-3'; reverse primer, 5'-GTGAGAAAAAGAAGCAATTACTTACATTC-3'. The following PCR parameters were used: 2 minutes at 50°C, 10 minutes at 95°C, 40 cycles of 15 seconds at 95°C, and 60 seconds at 60°C. Standard curves were established individually for both MFGS and HPRT by analyzing samples of serial dilutions of DNA from a K562 cell line with a single copy of MFGS vector per cell. All samples of interest were analyzed in triplicates, and copy number of MFGS vector was calculated using the standard curve and normalized using the results for HPRT. Transgene integration site analysis using a modified LAM-PCR Clonality assessment was performed using a modified protocol of previously described linear amplification-mediated (LAM)–PCR.27 In our modified assay, TasI was used as the frequent cutter restriction enzyme and PvuII to digest the 206-bp PCR product that derives from amplifying a vector sequence starting within the 3' long terminal repeat (LTR). Insertion site sequences were aligned to canine genomic sequences in collaboration with The Institute for Genomic Research (TIGR) and to the recently assembled canine genome using the UCSC genome browser (BLAT search28).
Intravenous administration of concentrated vector is well tolerated
Four 3-day-old XSCID puppies (weighing approximately 500 g each), dogs 1551, 1548, 1547, and 1655, were injected intravenously with escalating doses of concentrated RD1114-pseudotyped MFGS–canine-
Sustained transgene expression in both lymphoid and myeloid peripheral blood lineages following in vivo gene therapy Following intravenous injection of the bicistronic vector, transduced cells could be detected easily by flow cytometric measurement of GFP expression. All 4 treated XSCID dogs had detectable GFP expression in peripheral blood lymphocytes (3% to 15.8%), monocytes (0.5% to 5.6%), and granulocytes (0.5% to 6.1%) at 3 weeks after treatment, the earliest time point evaluated in each of these animals. The percentage of lymphocytes and, to a lesser extent, of monocytes in the peripheral blood that were GFP+ continued to increase in all the dogs between 3 and 8 weeks after treatment (up to 80%-85% GFP+ T lymphocytes), whereas the percentage of GFP+ granulocytes remained relatively constant. Figure 1 illustrates the strategy used for the flow cytometric analysis for GFP+ cells in the various cell lineages following in vivo gene therapy. Because of the nuclear localization sequence found in MGMT*, the GFP-MGMT* fusion protein is localized to the cell nucleus of the different lineages of peripheral blood cells (Figure 2), making it unlikely that any of the observed GFP marking is due to passive cytoplasmic transfer between cells. By 8 weeks after treatment, the T-cell proportion of peripheral blood lymphocytes had normalized for dogs 1548, 1547, and 1655 with at least 78% expressing GFP. Dog 1551 showed an increased T-cell percentage but clearly below the normal range (49%, with 71.1% being GFP+; Table 2). The absolute number of gene-corrected (GFP+) peripheral T cells also attained normal age-matched levels by 8 weeks after treatment in all the dogs except for dog 1551, which remained T-cell lymphopenic (Figure 3A; Table 2). Dog 1548 died at 9 weeks after treatment where, at necropsy, the cause of death was attributed to a severe anemia of uncertain cause. Histopathologically, there were no indications of an infection, marrow failure, or a malignant process. Blood loss was another possible cause of anemia and, retrospectively, an excessive amount of blood was noted to have been drawn for monitoring purposes. Dog 1551 suffered from recurrent chronic infections and severe weight loss, necessitating that the dog be humanely killed at 5 months after gene therapy treatment. Long-term follow-up of dogs 1547 (18 months) and 1655 (16 months) showed sustained marking (gene-corrected cells) in all blood cell lineages (Figure 3B). The proportion of GFP+ T cells remained stable between 80% and 85% in both dogs. Of particular note is the sustained transgene marking of the peripheral B cells (up to 26%) and of the myeloid lineages represented by GFP+ granulocytes (2% to 6%) and monocytes (2% to 12%), demonstrating persistence of even the myeloid marking following in vivo gene therapy.
Gene-marked circulating T lymphocytes express a CD45RA+ naive phenotype consistent with restored thymic function CD45RA+ T lymphocytes represent a population of unprimed (naive) T cells in contrast to the CD45RA– (CD45RO) primed/memory T cells. We observed that the majority of the newly emerging gene-marked T lymphocytes in the in vivo–treated dogs in this study expressed a CD45RA+ (naive) phenotype, suggesting that they were recent thymic emigrants. More than 90% of the GFP+ T cells in both long-term–surviving dogs, 1547 and 1655, at 4 months after treatment expressed a naive CD45RA+ phenotype compared with only 70% to 80% at 16 months after treatment (Figure 4A). This demonstrates a typical age-related decrease, similar to the pattern observed in normal, unaffected dogs at the same age.
Normal expression of the
Transgene expression as determined by GFP expression has remained unchanged after the initial 2 to 3 months in both dogs 1547 and 1655. More importantly, there has not been any evidence of overexpression of the
Gene-corrected lymphocytes exhibit normal function
More detailed immunologic and molecular analyses have been possible with the long-term–surviving animals. The gene-corrected T cells in both dog 1547 and dog 1655 attained normal function as evidenced by normal in vitro proliferation following mitogenic stimulation (data not shown) and stimulation with IL-2 (Figure 5A), responses not evident in untreated XSCID cells. The few GFP– cells that exhibit BrdU incorporation most likely represent the
Single transgene copy number in peripheral blood GFP+ lymphocytes but sparing of germ line cells
qPCR analysis of purified GFP+ lymphocytes at 15 months after treatment showed that the proviral copy number in dog 1547 averaged 1.13 copies per GFP+ T cell and in dog 1655, 1.07 copies per cell. Interestingly, purified GFP– T cells showed marking at similar levels consistent with the flow cytometric finding of
Polyclonal pattern of genomic vector insertion sites Vector integration site analysis on purified T cells by modified LAM-PCR demonstrated a highly polyclonal pattern for the long-term–surviving dogs 1547 and 1655 compared with an oligoclonal pattern for the relatively short-lived dog 1551 (Figure 6B). Serial LAM-PCRs (approximately every 3 months) have been performed and, so far, around 500 sequences have been analyzed, of which 30 unique insertion sites have human homologs. While additional analysis is ongoing, no insertion appeared to be in proximity of the LMO2 gene, a known oncogene in humans and associated with leukemia development in at least 2 patients following ex vivo gene therapy for XSCID,4,6 or any other currently known oncogene. Of note, there are no clones that have appeared dominant or increasing in representation over time in either of the long-term–surviving dogs. However, this does not necessarily preclude potentially harmful integration sites, and potential adverse events can only be determined by long-term monitoring of the treated dogs.
In this study we report for the first time immune reconstitution and reversal of the clinical phenotype of XSCID by direct intravenous injection of a retrovirus vector, encoding the normal canine c, in XSCID dogs. XSCID dogs that do not receive immune-corrective allogeneic bone marrow transplants or are not sustained in a strictly isolated gnotobiotic environment usually succumb to infection by 3 months of age.
Three of the 4 in vivo gene therapy–treated dogs attained normal numbers of gene-corrected peripheral T cells by 8 weeks following treatment. This finding is analogous to the cell development observed in XSCID dogs following successful HSC transplantation with purified CD34+ bone marrow cells.30 In 2 dogs that have been followed for 16 and 18 months, respectively, the absolute numbers of gene-corrected T cells have remained in the normal to high normal range. The reconstituted peripheral T cells in the treated dogs were functional as assessed by their ability to proliferate and phosphorylate STAT5 in response to cytokine stimulation. They also exhibited a diverse, polyclonal repertoire as determined by TCR V
One dog that received the lowest vector dose remained severely T-cell lymphopenic, and insertion site analysis demonstrated that the T lymphocytes in this dog were derived from a very limited number of clones. Although the animal survived longer than untreated XSCID dogs, it succumbed to chronic infections, suggesting a failure to achieve the level of clinical benefit seen in the other dogs. This suggests that, despite the selective growth advantage for Although some XSCID dogs, like some XSCID boys, can develop phenotypically mature T cells with age because of peripheral expansion, these nonfunctional T cells have an activated (CD45RA–) phenotype, and the dogs remain T-cell lymphopenic and do not survive past 3 months of age.33,34 At the time of treatment all dogs studied had a peripheral blood T-cell lymphopenia, which accounted for less than 0.5% of lymphocytes, making it highly unlikely that observed T-lymphocyte reconstitution was solely based upon transduction of peripheral T cells. In addition, the majority of gene-corrected T lymphocytes exhibited a naive (CD45RA+) phenotype, suggesting that these cells developed through a thymic-dependent pathway.35,36 In contrast to the XSCID boys treated by gene therapy, in whom the proportion of gene-corrected B cells remained 1% or less,3,37 the XSCID dogs treated by intravenous retroviral gene therapy exhibited B-cell chimerism as early as 4 weeks after treatment. More importantly, the 2 dogs monitored long-term have maintained significant proportions of gene-corrected B cells ranging from 11% to 26%. These 2 animals developed normal to low normal concentrations of serum IgG and specific IgG antibody production following immunization. The clinical significance of the presence of gene-corrected B lymphocytes is that both dogs have survived longer than 16 months without any supportive treatment with intravenous immunoglobulin. An interesting finding from this study was the sustained presence of gene-corrected monocytes and granulocytes, ranging between 2% and 12% and 2% and 6%, respectively. Persistent production of donor-derived myeloid cells is not observed following nonmyeloablative HSC transplantation in either XSCID boys or XSCID dogs, and in gene therapy–treated XSCID boys transgene was detected in 0.1% or less of myeloid cells.3 The presence of sustained levels of gene-marked myeloid cells for at least 18 months in our in vivo gene therapy XSCID dog study is highly suggestive of transduction of either multipotent HSCs or very primitive committed progenitors. The clinical significance of gene-corrected myeloid cells in XSCID is unclear; however, this level of marking may be significant for other diseases, where low levels of myeloid chimerism may be sufficient to correct the disease phenotype such as in the case of chronic granulomatous disease (CGD). No adverse side effects have been observed in either of the 2 long-term–monitored dogs. In particular, no pathologic clonal expansions have been detected by serial LAM-PCR analyses and none of the integration sites thus far examined have been in the proximity of known oncogenes. However, it should be stressed that this does not necessarily preclude potentially harmful integration sites. Because of the lifespan of dogs and the number of dogs that can be treated, canine XSCID provides an ideal large-animal, preclinical model in which to evaluate new strategies for gene therapy of XSCID and the potential long-term sequelae following gene transfer into long-lived HSCs including genotoxicity (effect of transgene insertion), phenotoxicity (effect of transgene expression), and selection toxicity (effect of cell expansion).38 Some gene-marking studies have reported marking in hematopoietic stem cells following different approaches to in vivo gene therapy.39-41 One potential concern for a clinical application of a direct intravenous approach to gene therapy in humans is the half-life of the vector in the bloodstream, based upon the observation that MLV-based retroviral vectors can be inactivated in the presence of human serum.42 However, RD114-pseudotyped viral vectors, such as the vector used in this study, have been reported to have an enhanced stability in human and nonhuman primate sera.43,44 A recent report of a phase 1 dose escalation clinical trial evaluating the intravenous injection of a vesicular stomatitis virus G-protein (VSV-G)–pseudotyped MLV-based vector expressing human FVIII in 13 hemophilia A patients showed that vector-positive peripheral blood mononuclear cells persisted for up to 53 weeks in the patients, suggesting that the used vector was not inactivated following intravenous injection.45 Thus an in vivo gene therapy approach may be feasible for humans. We also demonstrated in the study reported here that use of an RD114-pseudotyped viral vector does not result in the transduction of germ line cells. This is consistent with the reported absence of RD114 receptors in gonadal tissue,46 an important safety consideration for any in vivo gene therapy.
In summary, our study demonstrates that in vivo retroviral gene therapy by direct intravenous administration of a
We are grateful to Dr Patrick F. Kelly (Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, TN) for his generous gift of the FLYRD18 producer cells. We thank Dr Margaret L. Casal and Patty O'Donnell (Veterinary Hospital, University of Pennsylvania, Philadelphia) for the veterinary care of the XSCID dogs. We would like to also thank Dr Linda Burkly of Biogen Idec for providing the c monoclonal antibody used in this study, and Dr Meggan Czapiga of the National Institute of Allergy and Infectious Diseases, NIH, for collecting the confocal micrographs.
Submitted October 13, 2005; accepted December 9, 2005.
Prepublished online as Blood First Edition Paper, December 29, 2005; DOI 10.1182/blood-2005-10-4057.
Supported by the Intramural Research Program of the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases, and by NIH grant RO1 AI 43745 (P.J.F.).
H.L.M. and P.J.F. contributed equally to this study and share senior authorship.
An Inside Blood analysis of this article appears at the front of this issue.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Suk See Ting–De Ravin, Laboratory of Host Defenses, NIAID, NIH, Building 10-CRC, Room 5-3750, 10 Center Drive, Bethesda, MD 20892-1456; e-mail: sderavin{at}niaid.nih.gov.
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
variability analysis for clonality
), B cells (
), monocytes (
), and granulocytes (
) in dog 1547 (solid lines) and dog 1655 (broken lines).
indicates size of final vector control band with incomplete digestion by PvuII.
